The humoral immune response to high-dose influenza vaccine in persons with monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL)
•First published vaccine responses in those with monoclonal B cell lymphocytosis (MBL).•High-dose influenza vaccine responses in MBL and chronic lymphocytic leukemia (CLL).•Seroprotection: 63% (A/H1N1); 91% (A/H3N2); and 43% (B) for cohort (MBL and CLL).•Higher seroprotection rates for influenza B s...
Saved in:
| Published in | Vaccine Vol. 39; no. 7; pp. 1122 - 1130 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Elsevier Ltd
12.02.2021
Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0264-410X 1873-2518 1873-2518 |
| DOI | 10.1016/j.vaccine.2021.01.001 |
Cover
| Abstract | •First published vaccine responses in those with monoclonal B cell lymphocytosis (MBL).•High-dose influenza vaccine responses in MBL and chronic lymphocytic leukemia (CLL).•Seroprotection: 63% (A/H1N1); 91% (A/H3N2); and 43% (B) for cohort (MBL and CLL).•Higher seroprotection rates for influenza B seen were in those with MBL than CLL.
Limited data are available regarding the immunogenicity of high-dose influenza vaccine among persons with chronic lymphocytic leukemia (CLL) and monoclonal B cell lymphocytosis (MBL).
A prospective pilot study of humoral immune responses to 2013–2014 and 2014–2015 high-dose trivalent influenza vaccine (HD IIV; Fluzone® High-Dose; Sanofi Pasteur) was conducted among individuals with MBL and previously untreated CLL. Serum hemagglutination inhibition (HAI) antibody titers were measured at baseline and Day 28 after vaccination; seroprotection and seroconversion rates were determined. Memory B cell responses were assessed by B-cell enzyme-linked immune absorbent spotassays.
Thirty subjects (17 CLL and 13 MBL) were included. Median age was 69.5 years. Day 28 seroprotection rates for the cohort were 19/30 (63.3%) for A/H1N1; 21/23 (91.3%) for A/H3N2; and 13/30 (43.3%) for influenza B. Those with MBL achieved higher day 28 HAI geometric mean titers (54.1 [4.9, 600.1] vs. 12.1 [1.3, 110.1]; p = 0.01) and higher Day 28 seroprotection rates (76.9% vs. 17.6%; p = 0.002) against the influenza B-vaccine strain virus than those with CLL.
Immunogenicity of the HD IIV3 in patients with CLL and MBL is lower than reported in healthy adults. Immunogenicity to influenza B was greater in those with MBL than CLL. |
|---|---|
| AbstractList | Limited data are available regarding the immunogenicity of high-dose influenza vaccine among persons with chronic lymphocytic leukemia (CLL) and monoclonal B cell lymphocytosis (MBL).A prospective pilot study of humoral immune responses to 2013–2014 and 2014–2015 high-dose trivalent influenza vaccine (HD IIV; Fluzone® High-Dose; Sanofi Pasteur) was conducted among individuals with MBL and previously untreated CLL. Serum hemagglutination inhibition (HAI) antibody titers were measured at baseline and Day 28 after vaccination; seroprotection and seroconversion rates were determined. Memory B cell responses were assessed by B-cell enzyme-linked immune absorbent spotassays.Thirty subjects (17 CLL and 13 MBL) were included. Median age was 69.5 years. Day 28 seroprotection rates for the cohort were 19/30 (63.3%) for A/H1N1; 21/23 (91.3%) for A/H3N2; and 13/30 (43.3%) for influenza B. Those with MBL achieved higher day 28 HAI geometric mean titers (54.1 [4.9, 600.1] vs. 12.1 [1.3, 110.1]; p = 0.01) and higher Day 28 seroprotection rates (76.9% vs. 17.6%; p = 0.002) against the influenza B-vaccine strain virus than those with CLL.Immunogenicity of the HD IIV3 in patients with CLL and MBL is lower than reported in healthy adults. Immunogenicity to influenza B was greater in those with MBL than CLL. •First published vaccine responses in those with monoclonal B cell lymphocytosis (MBL).•High-dose influenza vaccine responses in MBL and chronic lymphocytic leukemia (CLL).•Seroprotection: 63% (A/H1N1); 91% (A/H3N2); and 43% (B) for cohort (MBL and CLL).•Higher seroprotection rates for influenza B seen were in those with MBL than CLL. Limited data are available regarding the immunogenicity of high-dose influenza vaccine among persons with chronic lymphocytic leukemia (CLL) and monoclonal B cell lymphocytosis (MBL). A prospective pilot study of humoral immune responses to 2013–2014 and 2014–2015 high-dose trivalent influenza vaccine (HD IIV; Fluzone® High-Dose; Sanofi Pasteur) was conducted among individuals with MBL and previously untreated CLL. Serum hemagglutination inhibition (HAI) antibody titers were measured at baseline and Day 28 after vaccination; seroprotection and seroconversion rates were determined. Memory B cell responses were assessed by B-cell enzyme-linked immune absorbent spotassays. Thirty subjects (17 CLL and 13 MBL) were included. Median age was 69.5 years. Day 28 seroprotection rates for the cohort were 19/30 (63.3%) for A/H1N1; 21/23 (91.3%) for A/H3N2; and 13/30 (43.3%) for influenza B. Those with MBL achieved higher day 28 HAI geometric mean titers (54.1 [4.9, 600.1] vs. 12.1 [1.3, 110.1]; p = 0.01) and higher Day 28 seroprotection rates (76.9% vs. 17.6%; p = 0.002) against the influenza B-vaccine strain virus than those with CLL. Immunogenicity of the HD IIV3 in patients with CLL and MBL is lower than reported in healthy adults. Immunogenicity to influenza B was greater in those with MBL than CLL. BackgroundLimited data are available regarding the immunogenicity of high-dose influenza vaccine among persons with chronic lymphocytic leukemia (CLL) and monoclonal B cell lymphocytosis (MBL).MethodsA prospective pilot study of humoral immune responses to 2013–2014 and 2014–2015 high-dose trivalent influenza vaccine (HD IIV; Fluzone® High-Dose; Sanofi Pasteur) was conducted among individuals with MBL and previously untreated CLL. Serum hemagglutination inhibition (HAI) antibody titers were measured at baseline and Day 28 after vaccination; seroprotection and seroconversion rates were determined. Memory B cell responses were assessed by B-cell enzyme-linked immune absorbent spotassays.ResultsThirty subjects (17 CLL and 13 MBL) were included. Median age was 69.5 years. Day 28 seroprotection rates for the cohort were 19/30 (63.3%) for A/H1N1; 21/23 (91.3%) for A/H3N2; and 13/30 (43.3%) for influenza B. Those with MBL achieved higher day 28 HAI geometric mean titers (54.1 [4.9, 600.1] vs. 12.1 [1.3, 110.1]; p = 0.01) and higher Day 28 seroprotection rates (76.9% vs. 17.6%; p = 0.002) against the influenza B-vaccine strain virus than those with CLL.ConclusionsImmunogenicity of the HD IIV3 in patients with CLL and MBL is lower than reported in healthy adults. Immunogenicity to influenza B was greater in those with MBL than CLL. Limited data are available regarding the immunogenicity of high-dose influenza vaccine among persons with chronic lymphocytic leukemia (CLL) and monoclonal B cell lymphocytosis (MBL).BACKGROUNDLimited data are available regarding the immunogenicity of high-dose influenza vaccine among persons with chronic lymphocytic leukemia (CLL) and monoclonal B cell lymphocytosis (MBL).A prospective pilot study of humoral immune responses to 2013-2014 and 2014-2015 high-dose trivalent influenza vaccine (HD IIV; Fluzone® High-Dose; Sanofi Pasteur) was conducted among individuals with MBL and previously untreated CLL. Serum hemagglutination inhibition (HAI) antibody titers were measured at baseline and Day 28 after vaccination; seroprotection and seroconversion rates were determined. Memory B cell responses were assessed by B-cell enzyme-linked immune absorbent spotassays.METHODSA prospective pilot study of humoral immune responses to 2013-2014 and 2014-2015 high-dose trivalent influenza vaccine (HD IIV; Fluzone® High-Dose; Sanofi Pasteur) was conducted among individuals with MBL and previously untreated CLL. Serum hemagglutination inhibition (HAI) antibody titers were measured at baseline and Day 28 after vaccination; seroprotection and seroconversion rates were determined. Memory B cell responses were assessed by B-cell enzyme-linked immune absorbent spotassays.Thirty subjects (17 CLL and 13 MBL) were included. Median age was 69.5 years. Day 28 seroprotection rates for the cohort were 19/30 (63.3%) for A/H1N1; 21/23 (91.3%) for A/H3N2; and 13/30 (43.3%) for influenza B. Those with MBL achieved higher day 28 HAI geometric mean titers (54.1 [4.9, 600.1] vs. 12.1 [1.3, 110.1]; p = 0.01) and higher Day 28 seroprotection rates (76.9% vs. 17.6%; p = 0.002) against the influenza B-vaccine strain virus than those with CLL.RESULTSThirty subjects (17 CLL and 13 MBL) were included. Median age was 69.5 years. Day 28 seroprotection rates for the cohort were 19/30 (63.3%) for A/H1N1; 21/23 (91.3%) for A/H3N2; and 13/30 (43.3%) for influenza B. Those with MBL achieved higher day 28 HAI geometric mean titers (54.1 [4.9, 600.1] vs. 12.1 [1.3, 110.1]; p = 0.01) and higher Day 28 seroprotection rates (76.9% vs. 17.6%; p = 0.002) against the influenza B-vaccine strain virus than those with CLL.Immunogenicity of the HD IIV3 in patients with CLL and MBL is lower than reported in healthy adults. Immunogenicity to influenza B was greater in those with MBL than CLL.CONCLUSIONSImmunogenicity of the HD IIV3 in patients with CLL and MBL is lower than reported in healthy adults. Immunogenicity to influenza B was greater in those with MBL than CLL. Limited data are available regarding the immunogenicity of high-dose influenza vaccine among persons with chronic lymphocytic leukemia (CLL) and monoclonal B cell lymphocytosis (MBL). A prospective pilot study of humoral immune responses to 2013-2014 and 2014-2015 high-dose trivalent influenza vaccine (HD IIV; Fluzone® High-Dose; Sanofi Pasteur) was conducted among individuals with MBL and previously untreated CLL. Serum hemagglutination inhibition (HAI) antibody titers were measured at baseline and Day 28 after vaccination; seroprotection and seroconversion rates were determined. Memory B cell responses were assessed by B-cell enzyme-linked immune absorbent spotassays. Thirty subjects (17 CLL and 13 MBL) were included. Median age was 69.5 years. Day 28 seroprotection rates for the cohort were 19/30 (63.3%) for A/H1N1; 21/23 (91.3%) for A/H3N2; and 13/30 (43.3%) for influenza B. Those with MBL achieved higher day 28 HAI geometric mean titers (54.1 [4.9, 600.1] vs. 12.1 [1.3, 110.1]; p = 0.01) and higher Day 28 seroprotection rates (76.9% vs. 17.6%; p = 0.002) against the influenza B-vaccine strain virus than those with CLL. Immunogenicity of the HD IIV3 in patients with CLL and MBL is lower than reported in healthy adults. Immunogenicity to influenza B was greater in those with MBL than CLL. Highlights•First published vaccine responses in those with monoclonal B cell lymphocytosis (MBL). •High-dose influenza vaccine responses in MBL and chronic lymphocytic leukemia (CLL). •Seroprotection: 63% (A/H1N1); 91% (A/H3N2); and 43% (B) for cohort (MBL and CLL). •Higher seroprotection rates for influenza B seen were in those with MBL than CLL. |
| Author | Shanafelt, Tait D. Kay, Neil E. Call, Timothy G. Kendarian, Saad S. Parikh, Sameer A. Whitaker, Jennifer A. Kennedy, Richard B. Ding, Wei Poland, Gregory A. Grill, Diane E. Goergen, Krista M. |
| AuthorAffiliation | a Molecular Virology and Microbiology and Medicine, Infectious Diseases, Baylor College of Medicine One Baylor Plaza, MS-280, Houston, TX 77030, USA d Division of Hematology, Stanford University School of Medicine, 500 Pasteur Drive, Stanford, CA 94305, USA b Division of Infectious Diseases, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA e Division of General Internal Medicine and Vaccine Research Group, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA c Division of Hematology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA f Division of Biomedical Statistics and Informatics, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA |
| AuthorAffiliation_xml | – name: a Molecular Virology and Microbiology and Medicine, Infectious Diseases, Baylor College of Medicine One Baylor Plaza, MS-280, Houston, TX 77030, USA – name: e Division of General Internal Medicine and Vaccine Research Group, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA – name: d Division of Hematology, Stanford University School of Medicine, 500 Pasteur Drive, Stanford, CA 94305, USA – name: b Division of Infectious Diseases, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA – name: c Division of Hematology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA – name: f Division of Biomedical Statistics and Informatics, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA |
| Author_xml | – sequence: 1 givenname: Jennifer A. surname: Whitaker fullname: Whitaker, Jennifer A. email: jennifer.whitaker@bcm.edu organization: Molecular Virology and Microbiology and Medicine, Infectious Diseases, Baylor College of Medicine One Baylor Plaza, MS-280, Houston, TX 77030, USA – sequence: 2 givenname: Sameer A. surname: Parikh fullname: Parikh, Sameer A. organization: Division of Hematology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA – sequence: 3 givenname: Tait D. surname: Shanafelt fullname: Shanafelt, Tait D. organization: Division of Hematology, Stanford University School of Medicine, 500 Pasteur Drive, Stanford, CA 94305, USA – sequence: 4 givenname: Neil E. surname: Kay fullname: Kay, Neil E. organization: Division of Hematology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA – sequence: 5 givenname: Richard B. surname: Kennedy fullname: Kennedy, Richard B. organization: Division of General Internal Medicine and Vaccine Research Group, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA – sequence: 6 givenname: Diane E. surname: Grill fullname: Grill, Diane E. organization: Division of Biomedical Statistics and Informatics, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA – sequence: 7 givenname: Krista M. surname: Goergen fullname: Goergen, Krista M. organization: Division of Biomedical Statistics and Informatics, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA – sequence: 8 givenname: Timothy G. surname: Call fullname: Call, Timothy G. organization: Division of Hematology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA – sequence: 9 givenname: Saad S. surname: Kendarian fullname: Kendarian, Saad S. organization: Division of Hematology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA – sequence: 10 givenname: Wei surname: Ding fullname: Ding, Wei organization: Division of Hematology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA – sequence: 11 givenname: Gregory A. surname: Poland fullname: Poland, Gregory A. organization: Division of General Internal Medicine and Vaccine Research Group, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33461835$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNUtuO0zAQjdAi9gKfALLES_chxZfEcYRYxFbcpCIeWCTeLNeZbNxN7GInReVH-F0ctRSohIo0ki9zzvF45pwnJ9ZZSJLHBE8JJvzZcrpWWhsLU4opmeIYmNxLzogoWEpzIk6SM0x5lmYEfzlNzkNYYoxzRsoHySljGSeC5WfJj5sGUDN0zqsWma4bLCAPYeVsANQ71JjbJq1cPBhbtwPY7wrtHo43aAU-RCj6ZvoGdc463Tobla5TDW2L2k23apze9C6YgCYfrueXSNkK6cY7a_Tv_LiH4Q46o9BkNp9fPkzu16oN8Gi3XiSf37y-mb1L5x_fvp-9mqeas6JPWZFlmIuyLGvOMaW1IKCAYA51JSDnnGWMLmJiUVcLxilb5IVWeVFqoYtacXaRXG11V8Oig0qD7WMn5MqbTvmNdMrIvzPWNPLWraUgosQCR4HJTsC7rwOEXnYmjJ9XFtwQJM1pRgUvs_I4NCtKzESZ5RH69AC6dIOPnR1RIs8xKYux-Cd_Fr-v-td4IyDfArR3IXio9xCC5WgjuZS7acrRRhLHwCTynh_wtOlVb9zYA9MeZb_csiEObm3Ay6ANWA2V8aB7WTlzVOHqQEG3JhpGtXewgbDvBZGBSiw_jUYffU5J9HjkR4EX_xb4jwJ-AkG6EYU |
| CitedBy_id | crossref_primary_10_1038_s41375_022_01620_2 crossref_primary_10_1080_10428194_2022_2092857 crossref_primary_10_1111_ejh_13722 crossref_primary_10_3390_biology12040545 crossref_primary_10_1002_ajh_27119 crossref_primary_10_1111_bjh_18014 crossref_primary_10_1002_ajh_26388 crossref_primary_10_1111_jcmm_16565 crossref_primary_10_3324_haematol_2021_279196 crossref_primary_10_1182_blood_2022016279 crossref_primary_10_1038_s41408_022_00684_8 crossref_primary_10_1007_s00108_021_01164_0 crossref_primary_10_7774_cevr_2024_13_4_271 crossref_primary_10_1182_hem_V20_5_202359 crossref_primary_10_1371_journal_pmed_1004157 crossref_primary_10_31744_einstein_journal_2023AO0089 crossref_primary_10_1200_JCO_24_00332 crossref_primary_10_1016_j_hoc_2021_03_010 crossref_primary_10_1016_j_vaccine_2025_126723 crossref_primary_10_3390_jcm12041648 crossref_primary_10_1080_10428194_2022_2133538 crossref_primary_10_1155_2022_6831640 crossref_primary_10_1007_s11912_022_01198_z crossref_primary_10_1016_j_bneo_2024_100059 crossref_primary_10_1053_j_seminhematol_2024_01_003 crossref_primary_10_1182_blood_2022017814 crossref_primary_10_3390_vaccines10020182 crossref_primary_10_3390_ijms26020681 |
| Cites_doi | 10.1111/j.1365-2249.1992.tb06965.x 10.1159/000204315 10.1128/JVI.01065-06 10.1016/0145-2126(90)90044-A 10.3322/caac.20107 10.2119/molmed.2011.00480 10.1111/irv.12018 10.1016/S1473-3099(09)70175-6 10.1158/2159-8290.CD-NB2018-167 10.3109/10428199409056283 10.1038/leu.2009.287 10.1038/leu.2012.187 10.3389/fimmu.2019.02832 10.1182/blood.V100.2.635 10.1001/jamaoncol.2016.2437 10.3109/10428194.2012.706285 10.1080/10428194.2017.1347931 10.1111/bjh.13585 10.3324/haematol.2017.164285 10.1159/000040709 10.1002/ajh.23214 10.1089/vim.2013.0099 10.1016/S0002-9343(97)00003-X 10.1016/j.mayocp.2018.03.002 10.1080/1042819021000029993 10.1016/j.exger.2017.09.015 10.7326/0003-4819-113-7-525 10.1007/BF00368891 10.1056/NEJMoa1315727 10.1016/S0953-6205(01)00149-2 10.1182/blood.V57.3.418.418 10.1002/cncr.22094 10.1159/000204095 10.1093/bmb/ldn034 10.1016/j.vaccine.2009.03.024 10.3109/10428194.2013.856426 10.1002/ijc.2910270310 10.1086/513648 10.1002/cyto.b.20533 |
| ContentType | Journal Article |
| Copyright | 2021 Elsevier Ltd Copyright © 2021 Elsevier Ltd. All rights reserved. 2021. Elsevier Ltd |
| Copyright_xml | – notice: 2021 Elsevier Ltd – notice: Copyright © 2021 Elsevier Ltd. All rights reserved. – notice: 2021. Elsevier Ltd |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7RV 7T2 7T5 7U9 7X7 7XB 88C 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K9- K9. KB0 LK8 M0R M0S M0T M1P M2O M7N M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 7S9 L.6 5PM |
| DOI | 10.1016/j.vaccine.2021.01.001 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Nursing & Allied Health Database Health and Safety Science Abstracts (Full archive) Immunology Abstracts Virology and AIDS Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) ProQuest Pharma Collection ProQuest Public Health Database ProQuest SciTech Collection ProQuest Natural Science Journals Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library ProQuest Central (Alumni) ProQuest One Sustainability (subscription) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep AIDS and Cancer Research Abstracts SciTech Premium Collection Consumer Health Database ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Biological Sciences Consumer Health Database (subscription) ProQuest Health & Medical Collection Healthcare Administration Database Medical Database Research Library Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic AGRICOLA AGRICOLA - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Research Library Prep ProQuest Central Student ProQuest Central Essentials SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library Health & Safety Science Abstracts ProQuest Public Health ProQuest Central Basic ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest SciTech Collection ProQuest Medical Library Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | AGRICOLA Research Library Prep MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Veterinary Medicine Biology Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1873-2518 |
| EndPage | 1130 |
| ExternalDocumentID | PMC8189080 33461835 10_1016_j_vaccine_2021_01_001 S0264410X21000013 1_s2_0_S0264410X21000013 |
| Genre | Journal Article Research Support, N.I.H., Extramural |
| GeographicLocations | California Northern Hemisphere United States--US Massachusetts |
| GeographicLocations_xml | – name: California – name: United States--US – name: Massachusetts – name: Northern Hemisphere |
| GrantInformation_xml | – fundername: NIAID NIH HHS grantid: R01 AI132348 – fundername: NIAID NIH HHS grantid: R01 AI138965 – fundername: NIAID NIH HHS grantid: U01 AI089859 – fundername: NCI NIH HHS grantid: R01 CA197120 – fundername: NCI NIH HHS grantid: P30 CA015083 – fundername: NCI NIH HHS grantid: R01 CA235026 |
| GroupedDBID | --- --K --M .1- .FO .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 4.4 457 4G. 53G 5RE 5VS 7-5 71M 7RV 7X7 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8G5 8P~ 9JM AAAJQ AABNK AAEDT AAEDW AAHBH AAIKJ AAKOC AALRI AAOAW AAQFI AARKO AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABKYH ABMAC ABMZM ABRWV ABUWG ACDAQ ACGFO ACGFS ACIEU ACIUM ACPRK ACRLP ACVFH ADBBV ADCNI ADEZE ADFRT AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEUYN AEVXI AEXOQ AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGCQF AGEKW AGGSO AGUBO AGYEJ AHMBA AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AQUVI AXJTR AZQEC BBNVY BENPR BHPHI BKEYQ BKNYI BKOJK BLXMC BNPGV BPHCQ BVXVI CCPQU CJTIS CNWQP CS3 DWQXO EBS EFJIC EFKBS EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN FYUFA G-Q GBLVA GNUQQ GUQSH HCIFZ HMCUK IHE J1W K9- KOM L7B LK8 LUGTX LW9 M0R M0T M1P M29 M2O M41 M7P MO0 N9A NAPCQ O-L O9- O9~ OAUVE OK0 OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PUEGO Q38 ROL RPZ SAB SCC SDF SDG SDP SES SNL SPCBC SSH SSI SSZ T5K UKHRP UV1 WH7 WOW Z5R ~G- .GJ 29Q 3V. AACTN AAQXK ABWVN ABXDB ACRPL ADMUD ADNMO ADVLN AFCTW AFJKZ AFKWA AGHFR AHHHB AJOXV ALIPV AMFUW ASPBG AVWKF AZFZN EJD FEDTE FGOYB G-2 HEJ HLV HMG HMK HMO HVGLF HX~ HZ~ R2- RIG SAE SEW SIN SVS WUQ XPP ZGI ZXP AAIAV ABLVK ABYKQ AESVU EFLBG LCYCR QYZTP AAYXX ACLOT ACMHX ADSLC AGQPQ AGWPP CITATION ~HD AGRNS CGR CUY CVF ECM EIF NPM 7QL 7T2 7T5 7U9 7XB 8FK C1K H94 K9. M7N MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 7S9 L.6 5PM |
| ID | FETCH-LOGICAL-c637t-3744068999f66022f81eae106efd8e5663432b022bfdb3623b57ca579c8c7fa63 |
| IEDL.DBID | .~1 |
| ISSN | 0264-410X 1873-2518 |
| IngestDate | Tue Sep 30 16:48:58 EDT 2025 Sat Sep 27 18:37:01 EDT 2025 Sun Sep 28 06:36:06 EDT 2025 Wed Aug 13 04:07:12 EDT 2025 Mon Jul 21 06:05:49 EDT 2025 Wed Oct 01 01:52:58 EDT 2025 Thu Apr 24 23:08:33 EDT 2025 Fri Feb 23 02:45:37 EST 2024 Tue Feb 25 19:57:06 EST 2025 Tue Aug 26 19:09:51 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Keywords | Influenza vaccines Lymphocytic Chronic B-cell Influenza Leukemia Monoclonal B cell lymphocytosis |
| Language | English |
| License | Copyright © 2021 Elsevier Ltd. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c637t-3744068999f66022f81eae106efd8e5663432b022bfdb3623b57ca579c8c7fa63 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Authorship J.A.W., T.D.S., S.A.P., T.D.S., N.E.K., R.B.K, and G.A.P. designed the research; J.A.W., T.D.S., S.A.P., T.D.S., N.E.K., R.B.K., T.C.G., W.D.D., S. S.K., and G.A.P. performed the experiments; J.A.W., T.D.S., S.A.P., T. D.S., N.E.K., R.B.K, D.E.G., and G.A.P. analyzed the results; J.A.W. wrote the manuscript; all authors critically revised and edited the manuscript for important intellectual content. All authors approved of the final version of the manuscript. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/8189080 |
| PMID | 33461835 |
| PQID | 2485501976 |
| PQPubID | 105530 |
| PageCount | 9 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8189080 proquest_miscellaneous_2524286949 proquest_miscellaneous_2479038945 proquest_journals_2485501976 pubmed_primary_33461835 crossref_primary_10_1016_j_vaccine_2021_01_001 crossref_citationtrail_10_1016_j_vaccine_2021_01_001 elsevier_sciencedirect_doi_10_1016_j_vaccine_2021_01_001 elsevier_clinicalkeyesjournals_1_s2_0_S0264410X21000013 elsevier_clinicalkey_doi_10_1016_j_vaccine_2021_01_001 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-02-12 |
| PublicationDateYYYYMMDD | 2021-02-12 |
| PublicationDate_xml | – month: 02 year: 2021 text: 2021-02-12 day: 12 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands – name: Kidlington |
| PublicationTitle | Vaccine |
| PublicationTitleAlternate | Vaccine |
| PublicationYear | 2021 |
| Publisher | Elsevier Ltd Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
| References | Scrivener, Goddard, Kaminski, Prentice (b0095) 2003; 44 Kay (b0100) 1981; 57 Gribabis, Panayiotidis, Boussiotis, Hannoun, Pangalis (b0160) 1994; 91 Griffiths, Lea, Bunch, Lee, Chapel (b0080) 1992; 89 Fiorcari, Maffei, Audrito, Martinelli, Ten Hacken, Zucchini (b0195) 2016; 7 Onodera, Urayama, Hirota, Maeda, Kubota-Koketsu, Takahashi (b0210) 2017; 11 Strati, Jain, O'Brien (b0040) 2018; 93 Yousuf, Englund, Couch, Rolston, Luna, Goodrich (b0015) 1997; 24 Dean, Moffatt, Rosewell, Dwyer, Lindley, Booy (b0220) 2010; 28 Rawstron, Green, Kuzmicki, Kennedy, Fenton, Evans (b0055) 2002; 100 Foon, Rai, Gale (b0090) 1990; 113 DiazGranados, Dunning, Kimmel, Kirby, Treanor, Collins (b0190) 2014; 371 Couch, Englund, Whimbey (b0010) 1997; 102 Bucalossi, Marotta, Galieni, Bigazzi, Valenzin, Dispensa (b0150) 1995; 93 Kelly, Sullivan, Grant, Fielding (b0225) 2013; 7 Freeman, Crassini, Best, Forsyth, Mackinlay, Han (b0070) 2013; 54 Briggs, Kraft, Atkins (b0110) 1990; 14 Hamblin, Hamblin (b0085) 2008; 87 van der Velden, Mulder, Hartkamp, Diepersloot, van Velzen-Blad, Biesma (b0140) 2001; 12 Sun, Gao, Couzens, Tian, Farooqui, Eichelberger (b0165) 2016; 2 Hauswirth, Almeida, Nieto, Teodosio, Rodriguez-Caballero, Romero (b0130) 2012; 87 Moreira, Rabe, Cerhan, Kay, Wilson, Call (b0060) 2013; 27 Wang, Taaffe, Parker, Solorzano, Cao, Garcia-Sastre (b0175) 2006; 80 Shanafelt, Kay, Parikh, Achenbach, Lesnick, Hanson (b0065) 2020 Kunisaki, Janoff (b0005) 2009; 9 Jemal, Bray, Center, Ferlay, Ward, Forman (b0025) 2011; 61 Marotta, Bucalossi, Galieni, Bigazzi, Nuti, Valenzin (b0145) 1998; 99 Francis, Karanth, Pratt, Starczynski, Hooper, Fegan (b0035) 2006; 107 Shanafelt, Ghia, Lanasa, Landgren, Rawstron (b0045) 2010; 24 Ntoufa, Vardi, Papakonstantinou, Anagnostopoulos, Aleporou-Marinou, Belessi (b0120) 2012; 18 Williams, Baran, Meacham, Feldman, Valencia, Newsom-Stewart (b0030) 2018; 59 Elting, Whimbey, Lo, Couch, Andreeff, Bodey (b0020) 1995; 3 Douglas, Trubiano, Barr, Leung, Slavin, Tam (b0170) 2017; 102 Painter, Haralambieva, Ovsyannikova, Grill, Poland (b0180) 2014; 27 Merani, Kuchel, Kleppinger, McElhaney (b0185) 2018; 107 Molica (b0075) 1994; 13 Ibrutinib may boost efficacy of CAR T cells. Cancer Discov 2019;9:OF3. doi: 10.1158/2159-8290.CD-NB2018-167. Barcellini, Imperiali, Zaninoni, Reda, Consonni, Fattizzo (b0125) 2014; 55 Jurlander, de Nully, Skov, Henrichsen, Heron, Obel (b0155) 1995; 9 Glancy, Siles (b0135) 2016; 173 Fiore, Bridges, Cox (b0215) 2009; 333 Parry, Mirajkar, Cutmore, Zuo, Long, Kwok (b0200) 2019; 10 Ziegler, Kay, Zarling (b0105) 1981; 27 Rawstron, Shanafelt, Lanasa, Landgren, Hanson, Orfao (b0050) 2010; 78 Ramsay, Johnson, Lee, Gorgun, Le Dieu, Blum (b0115) 2008; 118 Yousuf (10.1016/j.vaccine.2021.01.001_b0015) 1997; 24 Marotta (10.1016/j.vaccine.2021.01.001_b0145) 1998; 99 Ramsay (10.1016/j.vaccine.2021.01.001_b0115) 2008; 118 Rawstron (10.1016/j.vaccine.2021.01.001_b0050) 2010; 78 Shanafelt (10.1016/j.vaccine.2021.01.001_b0065) 2020 Parry (10.1016/j.vaccine.2021.01.001_b0200) 2019; 10 Gribabis (10.1016/j.vaccine.2021.01.001_b0160) 1994; 91 Molica (10.1016/j.vaccine.2021.01.001_b0075) 1994; 13 Bucalossi (10.1016/j.vaccine.2021.01.001_b0150) 1995; 93 Douglas (10.1016/j.vaccine.2021.01.001_b0170) 2017; 102 Shanafelt (10.1016/j.vaccine.2021.01.001_b0045) 2010; 24 Rawstron (10.1016/j.vaccine.2021.01.001_b0055) 2002; 100 Francis (10.1016/j.vaccine.2021.01.001_b0035) 2006; 107 Hamblin (10.1016/j.vaccine.2021.01.001_b0085) 2008; 87 Foon (10.1016/j.vaccine.2021.01.001_b0090) 1990; 113 Painter (10.1016/j.vaccine.2021.01.001_b0180) 2014; 27 Moreira (10.1016/j.vaccine.2021.01.001_b0060) 2013; 27 Freeman (10.1016/j.vaccine.2021.01.001_b0070) 2013; 54 Griffiths (10.1016/j.vaccine.2021.01.001_b0080) 1992; 89 Kay (10.1016/j.vaccine.2021.01.001_b0100) 1981; 57 Hauswirth (10.1016/j.vaccine.2021.01.001_b0130) 2012; 87 Fiorcari (10.1016/j.vaccine.2021.01.001_b0195) 2016; 7 Onodera (10.1016/j.vaccine.2021.01.001_b0210) 2017; 11 Kelly (10.1016/j.vaccine.2021.01.001_b0225) 2013; 7 Strati (10.1016/j.vaccine.2021.01.001_b0040) 2018; 93 Ntoufa (10.1016/j.vaccine.2021.01.001_b0120) 2012; 18 Briggs (10.1016/j.vaccine.2021.01.001_b0110) 1990; 14 Elting (10.1016/j.vaccine.2021.01.001_b0020) 1995; 3 Jemal (10.1016/j.vaccine.2021.01.001_b0025) 2011; 61 Williams (10.1016/j.vaccine.2021.01.001_b0030) 2018; 59 van der Velden (10.1016/j.vaccine.2021.01.001_b0140) 2001; 12 Wang (10.1016/j.vaccine.2021.01.001_b0175) 2006; 80 Sun (10.1016/j.vaccine.2021.01.001_b0165) 2016; 2 Glancy (10.1016/j.vaccine.2021.01.001_b0135) 2016; 173 Barcellini (10.1016/j.vaccine.2021.01.001_b0125) 2014; 55 Kunisaki (10.1016/j.vaccine.2021.01.001_b0005) 2009; 9 Merani (10.1016/j.vaccine.2021.01.001_b0185) 2018; 107 Couch (10.1016/j.vaccine.2021.01.001_b0010) 1997; 102 10.1016/j.vaccine.2021.01.001_b0205 Jurlander (10.1016/j.vaccine.2021.01.001_b0155) 1995; 9 Scrivener (10.1016/j.vaccine.2021.01.001_b0095) 2003; 44 Ziegler (10.1016/j.vaccine.2021.01.001_b0105) 1981; 27 Fiore (10.1016/j.vaccine.2021.01.001_b0215) 2009; 333 Dean (10.1016/j.vaccine.2021.01.001_b0220) 2010; 28 DiazGranados (10.1016/j.vaccine.2021.01.001_b0190) 2014; 371 |
| References_xml | – volume: 55 start-page: 1768 year: 2014 end-page: 1773 ident: b0125 article-title: Toll-like receptor 4 and 9 expression in B-chronic lymphocytic leukemia: relationship with infections, autoimmunity and disease progression publication-title: Leuk Lymphoma – volume: 78 start-page: S19 year: 2010 end-page: S23 ident: b0050 article-title: Different biology and clinical outcome according to the absolute numbers of clonal B-cells in monoclonal B-cell lymphocytosis (MBL) publication-title: Cytometry B Clin Cytom – volume: 333 start-page: 43 year: 2009 end-page: 82 ident: b0215 article-title: Seasonal influenza vaccines publication-title: Curr Top Microbiol Immunol – volume: 102 start-page: e397 year: 2017 end-page: e399 ident: b0170 article-title: Ibrutinib may impair serological responses to influenza vaccination publication-title: Haematologica – volume: 10 start-page: 2832 year: 2019 ident: b0200 article-title: Long-term ibrutinib therapy reverses CD8(+) T cell exhaustion in B cell chronic lymphocytic leukaemia publication-title: Front Immunol – volume: 27 start-page: 32 year: 2014 end-page: 38 ident: b0180 article-title: Detection of influenza A/H1N1-specific human IgG-secreting B cells in older adults by ELISPOT assay publication-title: Viral Immunol – volume: 7 year: 2016 ident: b0195 article-title: Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia publication-title: Oncotarget – reference: Ibrutinib may boost efficacy of CAR T cells. Cancer Discov 2019;9:OF3. doi: 10.1158/2159-8290.CD-NB2018-167. – volume: 113 start-page: 525 year: 1990 end-page: 539 ident: b0090 article-title: Chronic lymphocytic leukemia: new insights into biology and therapy publication-title: Ann Intern Med – volume: 80 start-page: 11628 year: 2006 end-page: 11637 ident: b0175 article-title: Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines publication-title: J Virol – volume: 91 start-page: 115 year: 1994 end-page: 118 ident: b0160 article-title: Influenza virus vaccine in B-cell chronic lymphocytic leukaemia patients publication-title: Acta Haematol – volume: 371 start-page: 635 year: 2014 end-page: 645 ident: b0190 article-title: Efficacy of high-dose versus standard-dose influenza vaccine in older adults publication-title: N Engl J Med – volume: 18 start-page: 1281 year: 2012 end-page: 1291 ident: b0120 article-title: Distinct innate immunity pathways to activation and tolerance in subgroups of chronic lymphocytic leukemia with distinct immunoglobulin receptors publication-title: Mol Med – volume: 54 start-page: 99 year: 2013 end-page: 104 ident: b0070 article-title: Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia publication-title: Leuk Lymphoma – volume: 2 start-page: 1656 year: 2016 end-page: 1657 ident: b0165 article-title: Seasonal influenza vaccination in patients with chronic lymphocytic leukemia treated with ibrutinib publication-title: JAMA Oncol – volume: 93 start-page: 651 year: 2018 end-page: 664 ident: b0040 article-title: Chronic lymphocytic leukemia: diagnosis and treatment publication-title: Mayo Clin Proc – volume: 9 start-page: 493 year: 2009 end-page: 504 ident: b0005 article-title: Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses publication-title: Lancet Infect Dis – volume: 3 start-page: 198 year: 1995 end-page: 202 ident: b0020 article-title: Epidemiology of influenza A virus infection in patients with acute or chronic leukemia publication-title: Support Care Cancer – year: 2020 ident: b0065 article-title: Risk of serious infection among individuals with and without low count monoclonal B-cell lymphocytosis (MBL) publication-title: Leukemia – volume: 44 start-page: 383 year: 2003 end-page: 389 ident: b0095 article-title: Abnormal T-cell function in B-cell chronic lymphocytic leukaemia publication-title: Leuk Lymphoma – volume: 93 start-page: 56 year: 1995 ident: b0150 article-title: Immunological response to influenza virus vaccine in B-cell chronic lymphocytic leukaemia patients publication-title: Acta Haematol – volume: 59 start-page: 625 year: 2018 end-page: 632 ident: b0030 article-title: Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies publication-title: Leuk Lymphoma – volume: 27 start-page: 136 year: 2013 end-page: 141 ident: b0060 article-title: Infectious complications among individuals with clinical monoclonal B-cell lymphocytosis (MBL): a cohort study of newly diagnosed cases compared to controls publication-title: Leukemia – volume: 24 start-page: 1095 year: 1997 end-page: 1099 ident: b0015 article-title: Influenza among hospitalized adults with leukemia publication-title: Clin Infect Dis – volume: 107 start-page: 116 year: 2018 end-page: 125 ident: b0185 article-title: Influenza vaccine-mediated protection in older adults: Impact of influenza infection, cytomegalovirus serostatus and vaccine dosage publication-title: Exp Gerontol – volume: 89 start-page: 374 year: 1992 end-page: 377 ident: b0080 article-title: Predictors of infection in chronic lymphocytic leukaemia (CLL) publication-title: Clin Exp Immunol – volume: 57 start-page: 418 year: 1981 end-page: 420 ident: b0100 article-title: Abnormal T-cell subpopulation function in CLL: excessive suppressor (T gamma) and deficient helper (T mu) activity with respect to B-cell proliferation publication-title: Blood – volume: 118 start-page: 2427 year: 2008 end-page: 2437 ident: b0115 article-title: Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug publication-title: J Clin Invest – volume: 87 start-page: 49 year: 2008 end-page: 62 ident: b0085 article-title: The immunodeficiency of chronic lymphocytic leukaemia publication-title: Br Med Bull – volume: 100 start-page: 635 year: 2002 end-page: 639 ident: b0055 article-title: Monoclonal B lymphocytes with the characteristics of “indolent” chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts publication-title: Blood – volume: 173 start-page: 316 year: 2016 end-page: 317 ident: b0135 article-title: Monoclonal B-cell lymphocytosis and hypogammaglobulinaemia publication-title: Br J Haematol – volume: 102 start-page: 2 year: 1997 end-page: 9 ident: b0010 article-title: Respiratory viral infections in immunocompetent and immunocompromised persons publication-title: Am J Med – volume: 14 start-page: 155 year: 1990 end-page: 159 ident: b0110 article-title: T cells and CD45R expression in B-chronic lymphocytic leukemia publication-title: Leuk Res – volume: 24 start-page: 512 year: 2010 end-page: 520 ident: b0045 article-title: Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management publication-title: Leukemia – volume: 87 start-page: 721 year: 2012 end-page: 724 ident: b0130 article-title: Monoclonal B-cell lymphocytosis (MBL) with normal lymphocyte counts is associated with decreased numbers of normal circulating B-cell subsets publication-title: Am J Hematol – volume: 99 start-page: 18 year: 1998 end-page: 21 ident: b0145 article-title: CD4+/CD45RA+ 'naive' T cells and immunological response to influenza virus vaccine in B-cell chronic lymphocytic leukaemia patients publication-title: Acta Haematol – volume: 61 start-page: 69 year: 2011 end-page: 90 ident: b0025 article-title: Global cancer statistics publication-title: CA Cancer J Clin – volume: 9 start-page: 1902 year: 1995 end-page: 1909 ident: b0155 article-title: Improved vaccination response during ranitidine treatment, and increased plasma histamine concentrations, in patients with B cell chronic lymphocytic leukemia publication-title: Leukemia – volume: 13 start-page: 203 year: 1994 end-page: 214 ident: b0075 article-title: Infections in chronic lymphocytic leukemia: risk factors, and impact on survival, and treatment publication-title: Leuk Lymphoma – volume: 12 start-page: 420 year: 2001 end-page: 424 ident: b0140 article-title: Influenza virus vaccination and booster in B-cell chronic lymphocytic leukaemia patients publication-title: Eur J Intern Med – volume: 27 start-page: 321 year: 1981 end-page: 327 ident: b0105 article-title: Deficiency of natural killer cell activity in patients with chronic lymphocytic leukemia publication-title: Int J Cancer – volume: 11 start-page: 23 year: 2017 end-page: 30 ident: b0210 article-title: Neutralizing activities against seasonal influenza viruses in human intravenous immunoglobulin publication-title: Biologics – volume: 107 start-page: 1023 year: 2006 end-page: 1033 ident: b0035 article-title: The effect of immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia publication-title: Cancer – volume: 28 start-page: 864 year: 2010 end-page: 867 ident: b0220 article-title: Incompletely matched influenza vaccine still provides protection in frail elderly publication-title: Vaccine – volume: 7 start-page: 729 year: 2013 end-page: 737 ident: b0225 article-title: Moderate influenza vaccine effectiveness with variable effectiveness by match between circulating and vaccine strains in Australian adults aged 20–64 years, 2007–2011 publication-title: Influenza Other Respir Viruses – volume: 89 start-page: 374 year: 1992 ident: 10.1016/j.vaccine.2021.01.001_b0080 article-title: Predictors of infection in chronic lymphocytic leukaemia (CLL) publication-title: Clin Exp Immunol doi: 10.1111/j.1365-2249.1992.tb06965.x – volume: 91 start-page: 115 year: 1994 ident: 10.1016/j.vaccine.2021.01.001_b0160 article-title: Influenza virus vaccine in B-cell chronic lymphocytic leukaemia patients publication-title: Acta Haematol doi: 10.1159/000204315 – volume: 80 start-page: 11628 year: 2006 ident: 10.1016/j.vaccine.2021.01.001_b0175 article-title: Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines publication-title: J Virol doi: 10.1128/JVI.01065-06 – year: 2020 ident: 10.1016/j.vaccine.2021.01.001_b0065 article-title: Risk of serious infection among individuals with and without low count monoclonal B-cell lymphocytosis (MBL) publication-title: Leukemia – volume: 14 start-page: 155 year: 1990 ident: 10.1016/j.vaccine.2021.01.001_b0110 article-title: T cells and CD45R expression in B-chronic lymphocytic leukemia publication-title: Leuk Res doi: 10.1016/0145-2126(90)90044-A – volume: 61 start-page: 69 year: 2011 ident: 10.1016/j.vaccine.2021.01.001_b0025 article-title: Global cancer statistics publication-title: CA Cancer J Clin doi: 10.3322/caac.20107 – volume: 18 start-page: 1281 year: 2012 ident: 10.1016/j.vaccine.2021.01.001_b0120 article-title: Distinct innate immunity pathways to activation and tolerance in subgroups of chronic lymphocytic leukemia with distinct immunoglobulin receptors publication-title: Mol Med doi: 10.2119/molmed.2011.00480 – volume: 7 start-page: 729 year: 2013 ident: 10.1016/j.vaccine.2021.01.001_b0225 article-title: Moderate influenza vaccine effectiveness with variable effectiveness by match between circulating and vaccine strains in Australian adults aged 20–64 years, 2007–2011 publication-title: Influenza Other Respir Viruses doi: 10.1111/irv.12018 – volume: 9 start-page: 493 year: 2009 ident: 10.1016/j.vaccine.2021.01.001_b0005 article-title: Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(09)70175-6 – ident: 10.1016/j.vaccine.2021.01.001_b0205 doi: 10.1158/2159-8290.CD-NB2018-167 – volume: 11 start-page: 23 year: 2017 ident: 10.1016/j.vaccine.2021.01.001_b0210 article-title: Neutralizing activities against seasonal influenza viruses in human intravenous immunoglobulin publication-title: Biologics – volume: 13 start-page: 203 year: 1994 ident: 10.1016/j.vaccine.2021.01.001_b0075 article-title: Infections in chronic lymphocytic leukemia: risk factors, and impact on survival, and treatment publication-title: Leuk Lymphoma doi: 10.3109/10428199409056283 – volume: 24 start-page: 512 year: 2010 ident: 10.1016/j.vaccine.2021.01.001_b0045 article-title: Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management publication-title: Leukemia doi: 10.1038/leu.2009.287 – volume: 27 start-page: 136 year: 2013 ident: 10.1016/j.vaccine.2021.01.001_b0060 article-title: Infectious complications among individuals with clinical monoclonal B-cell lymphocytosis (MBL): a cohort study of newly diagnosed cases compared to controls publication-title: Leukemia doi: 10.1038/leu.2012.187 – volume: 10 start-page: 2832 year: 2019 ident: 10.1016/j.vaccine.2021.01.001_b0200 article-title: Long-term ibrutinib therapy reverses CD8(+) T cell exhaustion in B cell chronic lymphocytic leukaemia publication-title: Front Immunol doi: 10.3389/fimmu.2019.02832 – volume: 100 start-page: 635 year: 2002 ident: 10.1016/j.vaccine.2021.01.001_b0055 article-title: Monoclonal B lymphocytes with the characteristics of “indolent” chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts publication-title: Blood doi: 10.1182/blood.V100.2.635 – volume: 2 start-page: 1656 year: 2016 ident: 10.1016/j.vaccine.2021.01.001_b0165 article-title: Seasonal influenza vaccination in patients with chronic lymphocytic leukemia treated with ibrutinib publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2016.2437 – volume: 54 start-page: 99 year: 2013 ident: 10.1016/j.vaccine.2021.01.001_b0070 article-title: Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia publication-title: Leuk Lymphoma doi: 10.3109/10428194.2012.706285 – volume: 59 start-page: 625 year: 2018 ident: 10.1016/j.vaccine.2021.01.001_b0030 article-title: Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies publication-title: Leuk Lymphoma doi: 10.1080/10428194.2017.1347931 – volume: 173 start-page: 316 year: 2016 ident: 10.1016/j.vaccine.2021.01.001_b0135 article-title: Monoclonal B-cell lymphocytosis and hypogammaglobulinaemia publication-title: Br J Haematol doi: 10.1111/bjh.13585 – volume: 102 start-page: e397 year: 2017 ident: 10.1016/j.vaccine.2021.01.001_b0170 article-title: Ibrutinib may impair serological responses to influenza vaccination publication-title: Haematologica doi: 10.3324/haematol.2017.164285 – volume: 99 start-page: 18 year: 1998 ident: 10.1016/j.vaccine.2021.01.001_b0145 article-title: CD4+/CD45RA+ 'naive' T cells and immunological response to influenza virus vaccine in B-cell chronic lymphocytic leukaemia patients publication-title: Acta Haematol doi: 10.1159/000040709 – volume: 87 start-page: 721 year: 2012 ident: 10.1016/j.vaccine.2021.01.001_b0130 article-title: Monoclonal B-cell lymphocytosis (MBL) with normal lymphocyte counts is associated with decreased numbers of normal circulating B-cell subsets publication-title: Am J Hematol doi: 10.1002/ajh.23214 – volume: 27 start-page: 32 year: 2014 ident: 10.1016/j.vaccine.2021.01.001_b0180 article-title: Detection of influenza A/H1N1-specific human IgG-secreting B cells in older adults by ELISPOT assay publication-title: Viral Immunol doi: 10.1089/vim.2013.0099 – volume: 118 start-page: 2427 year: 2008 ident: 10.1016/j.vaccine.2021.01.001_b0115 article-title: Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug publication-title: J Clin Invest – volume: 102 start-page: 2 year: 1997 ident: 10.1016/j.vaccine.2021.01.001_b0010 article-title: Respiratory viral infections in immunocompetent and immunocompromised persons publication-title: Am J Med doi: 10.1016/S0002-9343(97)00003-X – volume: 93 start-page: 651 year: 2018 ident: 10.1016/j.vaccine.2021.01.001_b0040 article-title: Chronic lymphocytic leukemia: diagnosis and treatment publication-title: Mayo Clin Proc doi: 10.1016/j.mayocp.2018.03.002 – volume: 7 issue: 65968–81 year: 2016 ident: 10.1016/j.vaccine.2021.01.001_b0195 article-title: Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia publication-title: Oncotarget – volume: 44 start-page: 383 year: 2003 ident: 10.1016/j.vaccine.2021.01.001_b0095 article-title: Abnormal T-cell function in B-cell chronic lymphocytic leukaemia publication-title: Leuk Lymphoma doi: 10.1080/1042819021000029993 – volume: 9 start-page: 1902 year: 1995 ident: 10.1016/j.vaccine.2021.01.001_b0155 article-title: Improved vaccination response during ranitidine treatment, and increased plasma histamine concentrations, in patients with B cell chronic lymphocytic leukemia publication-title: Leukemia – volume: 107 start-page: 116 year: 2018 ident: 10.1016/j.vaccine.2021.01.001_b0185 article-title: Influenza vaccine-mediated protection in older adults: Impact of influenza infection, cytomegalovirus serostatus and vaccine dosage publication-title: Exp Gerontol doi: 10.1016/j.exger.2017.09.015 – volume: 113 start-page: 525 year: 1990 ident: 10.1016/j.vaccine.2021.01.001_b0090 article-title: Chronic lymphocytic leukemia: new insights into biology and therapy publication-title: Ann Intern Med doi: 10.7326/0003-4819-113-7-525 – volume: 3 start-page: 198 year: 1995 ident: 10.1016/j.vaccine.2021.01.001_b0020 article-title: Epidemiology of influenza A virus infection in patients with acute or chronic leukemia publication-title: Support Care Cancer doi: 10.1007/BF00368891 – volume: 371 start-page: 635 year: 2014 ident: 10.1016/j.vaccine.2021.01.001_b0190 article-title: Efficacy of high-dose versus standard-dose influenza vaccine in older adults publication-title: N Engl J Med doi: 10.1056/NEJMoa1315727 – volume: 12 start-page: 420 year: 2001 ident: 10.1016/j.vaccine.2021.01.001_b0140 article-title: Influenza virus vaccination and booster in B-cell chronic lymphocytic leukaemia patients publication-title: Eur J Intern Med doi: 10.1016/S0953-6205(01)00149-2 – volume: 333 start-page: 43 year: 2009 ident: 10.1016/j.vaccine.2021.01.001_b0215 article-title: Seasonal influenza vaccines publication-title: Curr Top Microbiol Immunol – volume: 57 start-page: 418 year: 1981 ident: 10.1016/j.vaccine.2021.01.001_b0100 article-title: Abnormal T-cell subpopulation function in CLL: excessive suppressor (T gamma) and deficient helper (T mu) activity with respect to B-cell proliferation publication-title: Blood doi: 10.1182/blood.V57.3.418.418 – volume: 107 start-page: 1023 year: 2006 ident: 10.1016/j.vaccine.2021.01.001_b0035 article-title: The effect of immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia publication-title: Cancer doi: 10.1002/cncr.22094 – volume: 93 start-page: 56 year: 1995 ident: 10.1016/j.vaccine.2021.01.001_b0150 article-title: Immunological response to influenza virus vaccine in B-cell chronic lymphocytic leukaemia patients publication-title: Acta Haematol doi: 10.1159/000204095 – volume: 87 start-page: 49 year: 2008 ident: 10.1016/j.vaccine.2021.01.001_b0085 article-title: The immunodeficiency of chronic lymphocytic leukaemia publication-title: Br Med Bull doi: 10.1093/bmb/ldn034 – volume: 28 start-page: 864 year: 2010 ident: 10.1016/j.vaccine.2021.01.001_b0220 article-title: Incompletely matched influenza vaccine still provides protection in frail elderly publication-title: Vaccine doi: 10.1016/j.vaccine.2009.03.024 – volume: 55 start-page: 1768 year: 2014 ident: 10.1016/j.vaccine.2021.01.001_b0125 article-title: Toll-like receptor 4 and 9 expression in B-chronic lymphocytic leukemia: relationship with infections, autoimmunity and disease progression publication-title: Leuk Lymphoma doi: 10.3109/10428194.2013.856426 – volume: 27 start-page: 321 year: 1981 ident: 10.1016/j.vaccine.2021.01.001_b0105 article-title: Deficiency of natural killer cell activity in patients with chronic lymphocytic leukemia publication-title: Int J Cancer doi: 10.1002/ijc.2910270310 – volume: 24 start-page: 1095 year: 1997 ident: 10.1016/j.vaccine.2021.01.001_b0015 article-title: Influenza among hospitalized adults with leukemia publication-title: Clin Infect Dis doi: 10.1086/513648 – volume: 78 start-page: S19 issue: Suppl 1 year: 2010 ident: 10.1016/j.vaccine.2021.01.001_b0050 article-title: Different biology and clinical outcome according to the absolute numbers of clonal B-cells in monoclonal B-cell lymphocytosis (MBL) publication-title: Cytometry B Clin Cytom doi: 10.1002/cyto.b.20533 |
| SSID | ssj0005319 |
| Score | 2.4813924 |
| Snippet | •First published vaccine responses in those with monoclonal B cell lymphocytosis (MBL).•High-dose influenza vaccine responses in MBL and chronic lymphocytic... Highlights•First published vaccine responses in those with monoclonal B cell lymphocytosis (MBL). •High-dose influenza vaccine responses in MBL and chronic... Limited data are available regarding the immunogenicity of high-dose influenza vaccine among persons with chronic lymphocytic leukemia (CLL) and monoclonal B... BackgroundLimited data are available regarding the immunogenicity of high-dose influenza vaccine among persons with chronic lymphocytic leukemia (CLL) and... |
| SourceID | pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1122 |
| SubjectTerms | absorbents Adult Age Aged Allergy and Immunology Antibodies Antibodies, Viral B-cell B-Lymphocytes blood serum Blood tests Chemotherapy Chronic Chronic lymphocytic leukemia Drug dosages Flow cytometry hemagglutination Hemagglutination inhibition Hemagglutination Inhibition Tests Humans humoral immunity Immune response Immune response (humoral) Immune system Immunity, Humoral Immunogenicity Immunoglobulins Immunological memory Infections Influenza Influenza A Virus, H1N1 Subtype Influenza A Virus, H3N2 Subtype Influenza B Influenza Vaccines Influenza, Human - prevention & control Leukemia Leukemia, Lymphocytic, Chronic, B-Cell Lymphatic leukemia Lymphocytes B Lymphocytic lymphocytic leukemia Lymphocytosis Medical laboratories Memory cells Monoclonal B cell lymphocytosis Pilot Projects Population Prospective Studies Seasons Seroconversion Vaccination Vaccines viruses |
| SummonAdditionalLinks | – databaseName: ProQuest Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1fb9MwELdgCMQLggKjMJCR0LRJ85Y0Tpw8ITYxTahFk9hQ3yzHcbSMLilLi1S-CF-Xu9hJGEwbb23taxLnfPc73z9C3vmZyrSJAwaqzzAeq5gpHnIWAjYKlfbDuOlFMPkcHZ3yT9Nw6g7cahdW2crERlBnlcYz8j1bessH7fl-_p1h1yj0rroWGnfJPR-gCnK1mIo-xCNoGnuAmcEZ971pn8Gzd777Q2l0XYOJOPKbyp2uL8w1uulf7Pl3COUfOunwMXnkwCT9YN_-E3LHlANy37aXXA3Ig4lznA_I5rEtUb3aoSd9xlW9QzfpcV-8GmgGXzE-pknSpS35U_ILiOjZ8gLT-WmBKSWGXtroWkMXFcWixyyr4Ethm578VNQ9OfxC5w2sryke-lJYyErP0ACg-wz9BnS2Apaq9GpR1UVNtyb7422qyoxqW7i3H8fPZvnNXBSKbh2Mx9vPyOnhx5ODI-ZaOjAdBWIB4owDggAbL8mjCOBDHvtGGTBLTZ7FBqAl5rmmMJDmWQq6NUhDoVUoEh1rkasoeE7Wyqo0LwiFLZAKA6IaVAeHv0383Mt0GuaBSkaRyIeEty9TalfvHNtuzGQb2HYu3UpI5AHp-RjgNyS7HdncFvy4jSBqOUW22awgfyWopNsIxXWEpnZSpJa-rEfSk1-8BrV605F1xgRDEneUDihZAPQ_F91omVl21-n31pC87YZBziATqNJUS5wjEizGyMMb5oQA-OIo4cmQrNv90a1hEPAI1AdQiys7p5uAdc6vjpTFWVPvHDBlAobNy5tv_RV5iM_JmmY9G2Rtcbk0rwEwLtI3jVT4DX0vbJs priority: 102 providerName: ProQuest |
| Title | The humoral immune response to high-dose influenza vaccine in persons with monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL) |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0264410X21000013 https://www.clinicalkey.es/playcontent/1-s2.0-S0264410X21000013 https://dx.doi.org/10.1016/j.vaccine.2021.01.001 https://www.ncbi.nlm.nih.gov/pubmed/33461835 https://www.proquest.com/docview/2485501976 https://www.proquest.com/docview/2479038945 https://www.proquest.com/docview/2524286949 https://pubmed.ncbi.nlm.nih.gov/PMC8189080 |
| Volume | 39 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Baden-Württemberg Complete Freedom Collection (Elsevier) customDbUrl: eissn: 1873-2518 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: GBLVA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier ScienceDirect customDbUrl: eissn: 1873-2518 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: .~1 dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Complete Freedom Collection [SCCMFC] customDbUrl: eissn: 1873-2518 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: ACRLP dateStart: 20091030 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: ScienceDirect Freedom Collection customDbUrl: eissn: 1873-2518 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: AIKHN dateStart: 20091030 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVLSH databaseName: Elsevier Journals customDbUrl: mediaType: online eissn: 1873-2518 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: AKRWK dateStart: 19831201 isFulltext: true providerName: Library Specific Holdings – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1873-2518 dateEnd: 20250801 omitProxy: true ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: 7X7 dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1873-2518 dateEnd: 20250801 omitProxy: true ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: BENPR dateStart: 20020101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Public Health Database customDbUrl: eissn: 1873-2518 dateEnd: 20250801 omitProxy: true ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: 8C1 dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELemIRAvaJSvsoGMhKZNWtqm-XDyuFabCrRVBRvqm-U4jpbRJdXSIpUH_g3-Xe5iJ13ZxBAvaRL7miY93_0c3_2OkPd2LGKpAscC16csNxCBJVzPtTzARp6QtheUtQhGY39w7n6cetMt0q9yYTCs0th-bdNLa23OtM3TbM_TtP2lU_ryzrSrX1Ej4yeyf4FOt37eCPNwyuIe2NnC3ussnvZl67uQuHwN08SuXbJ3mtowd_in2_jzzzDKG37pdIc8MYCSHuvf_JRsqaxBHuoSk6sGeTQyi-cNsj_RNNWrI3q2zroqjug-nawJrEGm8RVjZMpEXVqJPyO_QIheLK8wpZ-mmFai6LWOsFV0kVMkPrbiHA5SXfjkh6DmzuEMnZfQvqD44peC7udyhpMA2rNw7YDOVqBWuVwt8iIt6MGoNzykIoup1OS963bcV8tv6ioV9KA_HB4-J-enJ2f9gWXKOljSd9gCTJoLKALmeWHi-wAhksBWQsHUVCVxoABeYq5rBA1REkfgX53IY1J4LJSBZInwnRdkO8sz9YpQGAYRU2CuwX248LWhnXRiGXmJI8Kuz5Imcas_k0vDeY6lN2a8Cm675OZJcNQB3rExyK9JWrXYXJN-3CfgV5rCq4xWsMEc3NJ9guwuQVUYS1Jwmxdd3uG3tL1JglpyY8D8y0X3KmXm9XU0tZ0N6LRJ3tXNYGtQCUSm8iX2YSESMrreX_p4APoCP3TDJnmpx0f9DB3H9cGFgDTbGDl1B-Q632zJ0ouS8xxwZQiTm9f_f9e75DEeWWUxnz2yvbheqjcAKBfR29JiwJZNGWyDPuw_OP7waTCGz97JePL5N-oce3I |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9NAEF6VIo4XBOEKFFgkqFqpbn2srweEaKFKaVJVIq38tqzXazUltUOdgMIf4V_wG5nx-qBQtbz0zfHu2LF3dg7PzDeEvLISkUgVOAaoPmWwQASGYC4zXLCNXCEtNyh7EQz2vN4B-xi50QL5VdfCYFplLRNLQZ3kEr-Rb2joLQu059vJVwO7RmF0tW6hodliV82_g8tWvNl5D-v72ra3Pwy3ekbVVcCQnuNPYUcxUGLgZoSp54EGSwNLCQWekUqTQIF1g6WWMQzEaRKDeHdi15fC9UMZSD8VngPXvUauM8dkiNXvR36bUuKUjUTArWEGs8yorRjaOF7_JiSGysElta0SKbTqQ3OOLvzX1v07ZfMPHbh9l9ypjFf6TnPbPbKgsg65odtZzjvk5qAK1HfI8r6GxJ6v0WFb4VWs0WW634JlA03nEPNxyqJgWpPfJz-BiB7NThA-gI6whEXRU53Nq-g0pwiybCQ5_BjpJis_BK2eHM7QSelGFBQ_MlNYuFyO0eGgmwbGKeh4Diycy_k0L0YFXRls9lepyBIqNVBwO47HavZFnYwEXdnq91cfkIMrWeyHZDHLM_WYUNhysa9ANYCqYnDZ0ErNRMZu6ojQ9vy0S1i9mFxW-OrY5mPM60S6Y169CY48wE0LEwq7ZL0hm2iAkcsIvJpTeF09C_Kegwq8jNA_j1AVldQquMULm5v8k1layWZk6-CP0yVBQ1kZZtrg-p-bLtXMzJv7tHu5S142wyDXkAlEpvIZzvFDBH9k7gVzXDAwAy9kYZc80vujeYeOwzxQV0Dtn9k5zQTEVT87ko2OSnx1sGFDcKSeXPzXX5BbveGgz_s7e7tPyW18ZqNsFLREFqenM_UMjNVp_LyUEJR8vmqR9BsW7qhH |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELfGEBMvCMpXYYCRYNqkZc2HEycPCLGNamPtNIkN9c04jqN1dElZWlD5R_hf-Ou4i5OGwbTxsrc09iVNfL6P3N3vCHnlJDJROvQsUH3aYqEMLcl8ZvlgG_lSOX5Y9iLo7wc7R-zDwB8skF91LQymVdYysRTUSa7wG3nHQG85oD07aZUWcbDdfTv-amEHKYy01u00DIvs6dl3cN-KN7vbsNavXbf7_nBrx6o6DFgq8PgEdhcDhQYuR5QGAWizNHS01OAl6TQJNVg6WHYZw0CcJjGIei_2uZI-j1SoeCoDD657g9zkMA3TyfiAN-klXtlUBFwcZjHHHjTVQ52TjW9SYdgc3FPXKVFDq540F-jFf-3ev9M3_9CH3bvkTmXI0neG8-6RBZ21yC3T2nLWIkv9KmjfIisHBh57tk4Pm2qvYp2u0IMGOBtoWp8wN6csEKY1-X3yE4jo8fQUoQToEMtZND0zmb2aTnKKgMtWksOPoWm48kPS6snhDB2XLkVB8YMzhYXL1QidD7ppYcyCjmbAzrmaTfJiWNDV_mZvjcosocqABjfjeKynX_TpUNLVrV5v7QE5upbFfkgWszzTjwmF7RdzDWoC1BaDy0ZOaicq9lNPRm7A0zZh9WIKVWGtY8uPkaiT6k5E9SYE8oCwHUwubJONOdnYgI1cRRDUnCLqSlqQ_QLU4VWE_CJCXVQSrBCOKFxhi492aTHbA9cEgrw2CeeUlZFmjK__uelyzcxifp9mX7fJy_kwyDhkApnpfIpzeIRAkMy_ZI4PxmYYRCxqk0dmf8zfoeexAFQXUPNzO2c-ATHWz49kw-MSax3s2QicqieX__UXZAmEkejt7u89Jbfxka2yZ9AyWZycTfUzsFsn8fNSQFDy-bol0m8aXqyC |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+humoral+immune+response+to+high-dose+influenza+vaccine+in+persons+with+monoclonal+B-cell+lymphocytosis+%28MBL%29+and+chronic+lymphocytic+leukemia+%28CLL%29&rft.jtitle=Vaccine&rft.au=Whitaker%2C+Jennifer+A&rft.au=Parikh%2C+Sameer+A&rft.au=Shanafelt%2C+Tait+D&rft.au=Kay%2C+Neil+E&rft.date=2021-02-12&rft.issn=0264-410X&rft_id=info:doi/10.1016%2Fj.vaccine.2021.01.001&rft.externalDBID=ECK1-s2.0-S0264410X21000013&rft.externalDocID=1_s2_0_S0264410X21000013 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0264-410X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0264-410X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0264-410X&client=summon |